Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) – Overview
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) – Companies Involved in Therapeutics Development
AbbVie Inc
Amgen Inc
Bristol-Myers Squibb Co
Merck & Co Inc
Nimbus Therapeutics LLC
Oncostellae SL
Pfizer Inc
Portola Pharmaceuticals Inc
Sareum Holdings Plc
Simcere Pharmaceutical Group
Takeda Pharmaceutical Co Ltd
Theravance Biopharma Inc
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) – Drug Profiles
ABBV-712 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARRY-624 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986165 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brepocitinib tosylate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cerdulatinib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDI-031232 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDI-031301 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDI-031407 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OST-122 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06826647 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-20347 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SART-1 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SDC-1801 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SDC-1802 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAK1, JAK2 and TYK2 for Diabetic Macular Edema – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Asthma – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Rheumatoid Arthritis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAKs for Lung Transplant Rejection – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit TYK2 for Autoimmune Diseases – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit TYK2 for Inflammation – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit TYK2 for Unspecified Indication – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit Tyrosine Kinase 2 for Inflammatory Diseases – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-1473 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-8236 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) – Dormant Products
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) – Discontinued Products
Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) – Product Development Milestones
Featured News & Press Releases
Dec 09, 2019: Portola Pharmaceuticals presents new interim data at the 61st ASH meeting on its oral SYK/JAK inhibitor Cerdulatinib in heavily pre-treated patients with relapsed/refractory follicular lymphoma
Dec 08, 2019: Portola Pharmaceuticals presents new interim data from ongoing phase 2a study of its oral SYK/JAK inhibitor cerdulatinib in heavily pre-treated T-Cell Malignancies
Dec 03, 2019: Theravance Biopharma announces dosing of first patient in phase 2 allergen challenge study of TD-8236, an investigational, Lung-selective, inhaled pan-janus kinase (JAK) inhibitor for inflammatory lung diseases
Dec 03, 2019: Dermavant announces first patient dosed in phase 2a clinical trial of topical dual JAK/Syk inhibitor Cerdulatinib for Vitiligo
Oct 30, 2019: Sareum presents data highlighting the anti-tumour activity of TYK2/JAK1 Inhibitor SDC-1802 in multiple cancer disease models via a novel immunotherapeutic mechanism of action
Oct 17, 2019: Sareum Holdings -Research Update -AACR-NCI-EORTC abstract
Sep 27, 2019: Sareum TYK2/JAK1 Inhibitor SDC-1802 Demonstrates Anti-tumour Activity in Multiple Cancer Disease Models
Sep 09, 2019: Theravance Biopharma reports positive results from phase 1 clinical trial of TD-8236, an investigational, lung-selective, inhaled Pan-Janus Kinase (JAK) inhibitor for inflammatory lung diseases
Jun 19, 2019: Portola presents new interim data on its oral SYK/JAK inhibitor cerdulatinib in heavily pre-treated patients with Relapsed/Refractory Follicular Lymphoma
May 21, 2019: Theravance Biopharma reports data from phase 1b study of TD-1473 in oral presentation at Digestive Disease Week (DDW) 2019
May 14, 2019: Theravance Biopharma announces data from phase 1b study of TD-1473 to be featured in oral presentation at Digestive Disease Week (DDW) 2019
Apr 23, 2019: Oncostellae expands partnering activities for OST-122 at the 2019 BIO Int’l Convention in Philadelphia
Mar 12, 2019: Theravance Biopharma announces first patient dosed in phase 2b/3 study of TD-1473 in patients with ulcerative colitis
Dec 06, 2018: Dermavant Sciences to present new data on Cerdulatinib for atopic dermatitis and vitiligo at the 3rd Annual Inflammatory Skin Disease Summit
Dec 03, 2018: Updated interim results from ongoing phase 2a study of Portola Pharmaceuticals’ oral Syk/JAK inhibitor Cerdulatinib continues to demonstrate clinical responses in heavily pre-treated T-Cell Malignancies
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AbbVie Inc, H2 2019
Pipeline by Amgen Inc, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Nimbus Therapeutics LLC, H2 2019
Pipeline by Oncostellae SL, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Portola Pharmaceuticals Inc, H2 2019
Pipeline by Sareum Holdings Plc, H2 2019
Pipeline by Simcere Pharmaceutical Group, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Pipeline by Theravance Biopharma Inc, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019
【掲載企業】
AbbVie Inc
Amgen Inc
Bristol-Myers Squibb Co
Merck & Co Inc
Nimbus Therapeutics LLC
Oncostellae SL
Pfizer Inc
Portola Pharmaceuticals Inc
Sareum Holdings Plc
Simcere Pharmaceutical Group
Takeda Pharmaceutical Co Ltd
Theravance Biopharma Inc
【免責事項】
https://www.marketreport.jp/reports-disclaimer